Want to see SE:ONCO full AI Analyst Report?
ONCO Stock Chart & Stats
kr1.65
kr0.04(2.18%)
At close: 4:00 PM EDT
kr1.65
kr0.04(2.18%)
Day’s Range― - ―
52-Week Rangekr1.26 - kr6.18
Previous CloseN/A
Volume1.31M
Average Volume (3M)2.88M
Market Cap
kr678.44M
Enterprise Valuekr595.78
Total Cash (Recent Filing)kr205.15M
Total Debt (Recent Filing)kr130.80M
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding381,148,130
10 Day Avg. Volume4,900,792
30 Day Avg. Volume2,877,176
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-18.53
Price to Sales (P/S)15.35
P/FCF Ratio-4.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.46
Revenue Forecast (FY)kr148.45M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth With Exceptional Gross MarginsStrong sales growth combined with a 98% gross margin indicates increasing commercial traction and attractive unit economics. If sustained, this combination can improve operating leverage, support reinvestment in the pipeline, and strengthen the company’s ability to scale European commercialization.
Large Protected European Opportunity And Potential Label ExpansionLong European exclusivity provides a durable period to build adoption before direct loss of protection, while the submitted third-line expansion could materially widen the eligible population. A successful regulatory outcome would increase commercial runway and improve the product’s growth potential.
Growing European Adoption And Distribution ReachTreatment experience across Europe, a growing prescriber base and expansion into 11 Central and Eastern European countries show that commercialization is broadening beyond a single market. This wider footprint can diversify revenue sources and create additional opportunities for durable product adoption.
Bears Say
Severe Ongoing Cash Burn Delays Self-funded SustainabilityDeeply negative operating and free cash flow means the business is still consuming substantial cash rather than funding operations internally. Continued burn increases dependence on external financing and leaves less flexibility to invest in growth, absorb setbacks, or reach the 2027 cash-flow target.
High Leverage And Recapitalization SensitivityMeaningful debt relative to the equity base raises financial risk while the company remains loss-making. Volatile equity and persistent debt obligations can constrain capital allocation, increase sensitivity to further losses, and make access to additional funding important before operations improve.
Uneven Market Access And Competitive ExecutionCommercial performance depends on navigating country-specific access conditions and competition, which can make revenue growth uneven even when underlying demand exists. These execution hurdles may delay market penetration, reduce near-term operating leverage, and complicate progress toward company-wide cash-flow positivity.
Oncopeptides AB News
ONCO FAQ
What was Oncopeptides AB’s price range in the past 12 months?
Oncopeptides AB lowest stock price was kr1.25 and its highest was kr6.18 in the past 12 months.
What is Oncopeptides AB’s market cap?
Oncopeptides AB’s market cap is kr678.44M.
When is Oncopeptides AB’s upcoming earnings report date?
Oncopeptides AB’s upcoming earnings report date is Nov 05, 2026 which is in 59 days.
How were Oncopeptides AB’s earnings last quarter?
Oncopeptides AB released its earnings results on Aug 27, 2026. The company reported -kr0.144 earnings per share for the quarter.
Is Oncopeptides AB overvalued?
According to Wall Street analysts Oncopeptides AB’s price is currently Overvalued.
Does Oncopeptides AB pay dividends?
Oncopeptides AB does not currently pay dividends.
What is Oncopeptides AB’s EPS estimate?
Oncopeptides AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncopeptides AB have?
Oncopeptides AB has 381,148,130 shares outstanding.
What happened to Oncopeptides AB’s price movement after its last earnings report?
Oncopeptides AB reported an EPS of -kr0.144 in its last earnings report. Following the earnings report the stock price went up 20.447%.
Which hedge fund is a major shareholder of Oncopeptides AB?
Currently, no hedge funds are holding shares in SE:ONCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncopeptides AB
Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate engineered to address multiple myeloma that has relapsed or become resistant to prior treatments in adult individuals. Founded in 2000, Oncopeptides AB (publ) conducts its main business from Stockholm, Sweden.
Technical Analysis
Alligator Bioscience AB
―
BioInvent International AB
―
Immunicum AB
―
Cantargia AB
―
Sprint Bioscience AB
―